This study shows a markedly reduced risk of de novo HCC among patients with chronic HCV–related compensated cirrhosis who received DAA treatment com...

Nature Reviews Gastroenterology & Hepatology, Published online: 07 February 2025; doi:10.1038/s41575-025-01044-0

Nature Reviews Gastroenterology & Hepatology, Published online: 07 February 2025; doi:10.1038/s41575-025-01044-0

We thank Tang et al1 for their commentary on our study2 evaluating the efficacy of a short (?4 cm) myotomy for the treatment of sigmoid-type achalasia.

We thank Daungsupawong and Wiwanitkit for their comments on our article.1 This prospective study was designed to provide safety and clinical outcomes data on transoral incisionless fundoplication (TIF) 2.0 performed by a more representative mixed group of gastroenterologists and surgeons with varied prior experience with TIF from academic and practice settings.2 Multiple published clinical trials have reported the high safety and efficacy of TIF for treatment of GERD, but our study is the first to report comparable excellent outcomes when TIF 2.0 is performed in the real-world setting in the United States.

Greetings from snowy Denver, Colorado, and welcome to the February issue of Gastrointestinal Endoscopy. We are deep into winter, but rest assured, spring is on its way. As always, you will find this issue packed to the rafters with valuable information for your endoscopic practice, whether you are a general endoscopist or an advanced therapeutic endoscopist. We begin this issue with multiple important guidelines and ASGE society documents. These cover a wide range of critical topics, including the management of gastric varices, inflammatory bowel disease, gastroesophageal reflux, and the use of GLP-1 agonists and related agents.

Pancreatic cancer patients may benefit from future precision treatments as a new study shows how some tumors may potentially be more susceptible to macrophage-based therapies, and clues behind why these tumors don't respond to existing immunotherapies.

We read with great interest the article by Bofill et al1 reporting a retrospective single-center study on the potential role of MRCP in optimizing the treatment of patients with endoscopically treated walled-off necrosis (WON). Of note, no recurrence of pancreatic fluid collection (PFC) was noted in patients receiving MRCP-based assessment of the pancreatic duct before the removal of transluminal stent(s). The researchers concluded that MRCP may identify patients harboring a high risk of PFC recurrence resulting from disconnected pancreatic duct syndrome (DPDS)2 for whom long-term indwelling plastic stent(s) prevented the recurrence effectively.

Cyst size, its growth rate, and diameter of the main pancreatic duct (MPD) are all associated with pancreatic carcinoma prevalence in intraductal papi...